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Summary.-The effectiveness of maltose tetrapalmitate (MTP) as an antitumour
immune adjuvant was verified by its comparison with other known immuno-
potentiators, namely BCG, Corynebacterium parvum, levamisole and pyran copoly-
mer. Copenhagen x Fisher 344/CRBL F1 hybrid male rats inoculated s.c. with the
Dunning R3327A prostatic adenocarcinoma were used as the test system. All animals
treated with immunoadjuvants showed a delay in tumour appearance and inhibition
of early tumour growth. MTP was found to be the most effective, followed by levami-
sole, BCG, pyran copolymer and C. parvum in order of decreasing efficacy. Intra-
tumoral treatment of small or large s.c. tumours with BCG, MTP and C. parvum
was ineffective in our cases. However, this treatment was effective with MTP and
BCG if they were used against a differentiated form of R3327 tumour. MTP and
levamisole were found to be equally effective when given orally in drinking water.
Experiments involving surgical excision of tumours followed by MTP therapy in
two s.c. implanted animal tumour models (viz. a poorly immunogenic ascites
mammary carcinoma 13762 in Fisher 344/CRBL rats, and an SV40 virus-induced
sarcoma of low immunogenicity in Syrian hamster) showed beneficial effects of
MTP on local tumour recurrence and tumour growth. Pre- and postoperative MTP
treatment was at least as effective as postoperative MTP treatment alone.
CANCER THERAPY with immunoadju-
vants has come to be recognized as a
useful adjunct to conventional modes of
cancer treatment (Hersh et al., 1977). At
present, clinical use of immunoadjuvants
is limited to Bacillus Calmette-Guerin
BCG), BCG-derived products, heat-killed
C. parvum, and levamisole. In addition,
pyran copolymer (Weissman et al., 1977),
glucan (Chihara et al., 1970) and synthetic
polynucleotides (Came & Moore, 1971)
have shown promise in animal experi-
ments as immuno-potentiators and as
antitumour agents. On the other hand,
some ofthese products show some toxicity
in animals and in humans and occasionally
cause tumour enhancement (Berd et al.,
1976; Hersh et al., 1977; Mohr et al., 1976).
Yarkoni & Rapp (1979) have described
use of BCG cell walls plus trehalose
dimycolate in mineral oil and Tween in
the cures of guinea-pigs bearing small
intradermal (i.d.) hepatoma Line 10
tumour, and regression of regional lymph
node metastasis. However, recent experi-
ments of Ribi et al. (1979) suggest caution
in the use of such mixtures, because of
accompanying toxicity.
We have recently described the syn-
thesis, immunopotentiating capabilities
and antitumour activity of a simple
glycolipid, maltose tetrapalmitate (Nigam
et al., 1978). This substance is non-
immunogenic, and was shown to be non-
toxic by several criteria. Its degradation
products (glucose, maltose and palmiticH. EL KAPPANY ET AL.
acid) are normal constituents of animal
tissues. Since maltose tetrapalmitate
(MTP) appeared to beasuitable compound
for clinical use as a substitute for the
currently used bacterial products and
chemically derived agents, we were inter-
ested to know whether its antitumour
potential was equivalent to that of the
available immunoadjuvants. We have
therefore compared the antitumour activi-
ties of BCG, C. parvum, levamisole, pyran
copolymer and MTP against a single
animal tumour model. The tumour chosen
was Dunning R3327 transplantable rat
prostatic adenocarcinoma, because of the
similarity of its growth rate, differentia-
tion and biochemical behaviour in vivo to
that of human prostatic cancer (Symoens
et al., 1978). It was transplanted s.c.
rather than i.d., because our intention was
to see whether immunoadjuvants would
prevent acceptance and growth of the
transplant at an observable site, where it
effectively vascularizes and proliferates,
and where it has been conventionally
transplanted for several years. J.d.
tumours are indeed rare, and they offer
little similarity to most human cancers
(Carbone, 1977). Comparisons were also
made between MTP and BCG given intra-
tumorally and between MTP and lev-
amisole given orally.
Considering that a pressing problem in
human cancer treatment is tumour recur-
rence and metastasis after surgical re-
moval of operable cancer, we were also
interested in determining whether MTP
immunotherapy after surgery would pro-
vide an inhibition of or delay in local
tumour recurrence and an inhibition ofits
subsequent growth. This paper describes
these results in two non-metastatic animal
tumour models.
MATERIALS AND METHODS
Animal. - Adult (Copenhagen x Fisher
344/CRBL) F1 hybrid male rats weighing
about 200 g were used in the experiment, and
were raised in our animal houses by crossing
inbred male Copenhagen rats with inbred
female Fisher 344/CRBL rats. Inbred Fisher
344/CRBL female rats and Syrian hamsters
were obtained from the Charles River Breed-
ing Co., St Constant, Quebec, Canada.
Tumours.-Differentiated and undifferen-
tiated forms of prostatic adenocarcinoma
Dunning R3327, which are carried s.c. in
(Copenhagen x Fisher) F1 hybrid male rats,
were kindly supplied by Dr Coffey of the
Johns Hopkins SchoolofMedicine, Baltimore,
Md. The undifferentiated form (R3327A) was
mainly used as the tumour model in the
immunoadjuvant comparative studies. The
differentiated form was used to study intra-
tumoral treatment with MTP and BCG. For
the experiments in tumour surgery the two
tumour-host systems used, with the sources
in parentheses, were as follows: mammary
adenocarcinoma 13762 (MAC) in Fisher 344/
CRBLrats (DrA. E. Bogden,MasonResearch
Institute, Worcester, Mass.) and cultures of
an SV40-induced sarcoma (Cl2TSV5S) in
Syrian hamsters (Dr P. Tournier, Centre
National de la Recherche Scientifique, Ville-
juif, France). The first tumour was main-
tained by weekly i.p. transplantation in
Fisher 344/CRBL rats. This tumour is very
poorly immunogenic, as shown by immuniza-
tion experiments, and has a TD50 dose of
< 100 cells. C12TSV5S cells were maintained
in culture at 37°C in a C02 incubator using
MEM containing 10% foetal calf serum and
1% kanamycin, and were subcultured at
regular intervals at confluence. Cl2TSV5S cells
have low immunogenicity and have a TD50
dose of3000 cells.
Immunoadjuvant treatments.-F1 male rats
were inoculated s.c. in the right flank with a
suspension of Dunning R3327A adeno-
carcinoma in RPMI 1640 medium (GIBCO,
Grand Island, N.Y.) supplemented with 15%
foetal calf serum (FCS), 100 iu penicillin and
100 ,ug streptomycin per ml. In each experi-
ment the same fixed number of tumour cells
(106-107) was inoculated into each animal.
A single dose of each immunoadjuvant was
administered s.c. in the left flank of the
animals in each group, the control group
receiving 0.9% NaCl, 1-2 h after tumour
inoculation. BCG was injected as a water
suspension, each animal receiving 6x 106
bacilli (Zbar et al., 1971); C. parvum was
injected as a 0.9% NaCl suspension at a dose
of 1 mg per rat (Woodruff et al., 1974);
levamisole was injected, after being diluted
in water, at a dose of 12-5 mg/kg body wt
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(IFaanes et al., 1977; Hawrylko, 1973; Wood-
ruff et al., 1974). Tumour size was determined
at intervals of 4-5 days by measurement of
the long and short axes of the tumour and
expressed as their product. BCG and MTP
were also used in dose-response studies.
Intratumoral injection of immunoadjuvant
w,as carried out with the above doses when
the s.c. tumours were large (2-3 cm in dia-
meter) or small (0-2-0-5 cm in diameter).
Oral treatment of rats with levamisole and
MTP was carried out via the daily water
intake (Fisher et al., 1978). Levamisole was
given to a total dose of 12-5 mg/rat and MTP,
10 jig/rat. The drinking water contained
15-6 mg levamisole or 50 jig MTP per 500 ml
tap water for each group.
The comparative values were extrapolated
in relation to tumour size by t test. Differ-
ences between groups were considered signifi-
cant if P for the comparison was 0 05 or
less.
Tumour development, surgical excision and
MTP treatment.-Fisher rats and Syrian
hamsters were inoculated s.c. in the back
with 107 MACand C12TSV5S cells respectively.
The animals were allowed food and water ad
libitum. When the tumours had grown to
-0-5-2 cm in diameter (except Exp. No. 4
in the Table, where the tumours were 2-3 cm
in diameter) they were surgically excised
under aseptic condition using sodium pento-
barbital (Abbott Laboratories Ltd, Montreal,
Canada)anaesthesia.Usingtheundilutedstock
solution (50 mg/ml), the rats were injected at a
level of 7-5 mg/100 g body wt (0 15 ml) and
the hamsters received 10 mg/100 g body wt
(0-2 ml). The wounds were closed with 9mm
Clay Adams wound clips. When the animals
had recovered from anaesthesia, they were
randomly divided into two groups: one group
was given 0-2 ml of 0-9%o NaCl s.c. in the
flank opposite to the tumour site, and the
other group similarly received 0-2 ml of MTP
solution (10 ,ug). This treatment was given
3 times a week and continued for about 3
weeks. Tumour reappearance at the original
site and the size of any tumours that devel-
oped were recorded every 2-3 days by
measurement of the long and short axes of
the tumour and expressed as their product.
When the effects of pre- and postoperative
MTP treatment were to be determined, MTP
was given 7 and 3 days before tumour
excision, and this treatment was continued
thrice w%eekly thereafter as described above.
RESULTS
Antiturnour activity of immunoadjuvants
Fig. 1 shows the combined results of 3
experiments on the efficacy of various
immunoadjuvants. (One of these experi-
ments did not include C. parvum and
pyran copolymer.) The criteria used to
compare antitumour activity were: the
percentage of tumour takes at 4 intervals
(Days 7, 11, 15 and 20) and the average
size of tumours that developed (Fig. 1).
The experiments were terminated when
most of the animals in each group had
sizeable tumours (Day 20). Palpable
tumours appeared as early as Day 7 in the
majority (62.5o%) of the controls and by
Day 15, all animals in this group had
tumours. In the MTP group, only 180%
tumour take was observed on Day 7 and
47%/ on Day 15. In contrast, in the BCG,
C. parvum and pyran copolymer groups,
tumour takes ranged from 33O/% on Day 7
to 880% on Day 15. With levamisole.
tumour takes were 26 and 58% on Days 7
and 15 respectively. On Day 20, 2 animals
were tumour-free in the levamisole group
and 1 in the MTP animals.
Comparison of average tumour size
revealed that on Day 7 the tumours in the
BCG, levamisole, C. parvum and pyran
copolymer groups were significantly (50-
66%) smaller than controls, but in the
MTP group they were 83% smaller than
the controls, and significantly smaller than
in the other groups. (This difference dis-
appeared by Days 11 and 15.) On Day 20,
the average tumour size was significantly
smaller in the MTP group than in the con-
trols and in the groups treated with all the
other adjuvants. On the basis of tumour
size, the adjuvants, in decreasing order of
efficiency, could be ranked as follows:
MTP, levamisole, BCG, pyran copolymer
and C. parvum.
Dose-response relationship for BCG
The poor efficacy of BCG in the above
experiment when compared to MTP raised
the possibility that we could be using an
ineffective dose of BCG bacilli and anH. EL KAPPANY ET AL.
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product of length and breadth
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for BCG (Day 11) and C. parvum (I
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C. parvum; ---l levamisole.
effective dose of MTP. We ther
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injection 2-4 h after tumour ir
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a newly obtained Dunning
prostatic tumour. It had an in v
rate greater than in the previc
ments. Inoculation of 106 tumoi
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in the control group. All animal
3 x 106 bacilli of BCG afte
inoculation developed tumours
day. When 6x 106 bacilli of BCG were
- tl used, 60% of animals developed tumours
-t"" on the 3rd day and 100% by the 6th day.
- ,.Zgt, The use of 12 x 106 bacilli ofBCG resulted
in 80% tumours by the 3rdday and 100%
/ j p'i^i by the 6th day.
/^ / / When the sizes of tumours in this
,/ / experiment werecompared,it wasobserved
,/^ that animals injected with 3x 106 BCG
j%/ bacilli had slightly smaller tumours on
Days 10 and 13 than the controls. Six and
12 x 106 BCG bacilli resulted in tumours
/{-- -- smaller than the controls on all days, and
more significantly so on Day 6. The differ-
ences among these dose levels were insig-
nificant, but they were significant when
compared to controls.
Intratumoral treatment with BCG, C. par-
vum and MTP
i--i*; -Groups of animals bearing s.c. R3327A
>- tumour, about 0 4 cm in diameter, were
ent with inoculated with 6 x 106 BCG bacilli or
iour size 1 mg C. parvum or 10 ,ug MTP into the
mntation. tumour mass. The tumours were measured
mber of
every 3rd day, and the animals observed
s (7, 11, for inflammatory reaction or granuloma ed as a formation. Tumours continued to grow at
in cm2.
en saline the control rate, and no antitumour effects
t-treated of either MTP, C. parvum or BCG were
P <0°05) found. However, when a slow-growing Day 20).
a and P. differentiated tumour was used, and BCG
compari- and MTP were used for treatment, they
,mificant. + ricant- proved to be effective and reduced the
A---t A tumour growth, though there were no
cures. The increases in tumour size during
28 days were: MTP, 4-fold; BCG, 9-fold;
efore com- controls, 27-fold.
of BCG at
X 106 and Comparison of antitumour activity by oral
is a single treatment with MTP and levamisole
ioculation. Since levamisole is known to show
iment was optimum antitumour action when given
; R3327A orally, we were interested in comparing
ivo growth the tumour incidence and growth when
)us experi- MTP and levamisole were each given
ur cells s.c. orally in drinking water. Tumours de-
fter 3 days veloped in all the control animals on Day 5
Ls receiving and in 80% of the animals receiving oral
r tumour MTP and levamisole. However, all the
on the 3rd animals in the treated group had tumours
-sdP6
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MAC 13762 tumour and two with ham-
sters bearing the C12TSV5S tumour.
In rats bearing the MAC tumour, it was
observed that MTP prevented tumour re-
appearance in 50% of the animals in
Exps 1 and 2 (Table). In contrast, the
control group had 100% tumour reappear-
ance at the original site within 1 week. In
treated animals, any locally recurrent
tumours were significantly smaller than in
the controls. In Exp. 3, it could be seen
that both the onset of postoperative
-. @ - A tumours and the increment in tumour size
were more rapid in the untreated animals
than in the MTP group. It was also found
that deaths began in the untreated animals
17 days after surgery and reached 50%0
I I mortality on Day 24. The treated animals, 3 5 7 9 11 13 on the other hand, had only 1 death on
DAYS AFTER TUMOUR Day 21. In Exp. 4 (Table) the tumour was
INOCULATION deliberately allowed to grow to a larger
-Effeet of oral treatment witlh leva- size (2-3 cm in diameter) before surgical
le and MTP on tumour growtlh. 15 removal. In this case the MTP effect was
ials were inoculatedl s.c. on one flank
106R3327A tumour cells. The animals diminished. Tumour recurrence took place
randomized into 3 groups of 5 each. in both control and MTP animals, though
Ip 1, no treatment; Group 2, 12-5 mg the average tumour size was still signi- nisole in drinking water; Group 3
MTP in drinking water. Details under ficantly less in the treated animals.
'rials and Methodls. Tumour takes and The results with hamsters bearing the
ur size were (letermined on alternate
. There was 100% tumour take on C12TSV5S tumour (Table) were even more
5 in the control group, whereas it was convincing. In the controls, in Exp. 1,
in Groups 2 and 3 on Day 5 and tumours reappeared in 4/10 animals
0on Day 7.0 O, control; * - -*,
a
nisole; A---A, MTP. MITP and whereas no tumour developed in 9 animals
nisole were significantly different receiving MTP up to 31 days after tumour
control on all days, and nonsigni- excision. The results of the second experi- tly different from eachl othier on all ment are described below, underCl2TSV5S.
by Day 7. The tumours in both MTP- and
levamisole-treated animals were signifi-
cantly smaller than the control on all the
days of observation. There was no signifi-
cant difference in tumour size between
MTP and levamisole-treated animals
(Fig. 2).
Effect of postoperative MTP on tum2our
recurrence and growth
The effect of MTP on local tumour re-
appearance and size in animals from which
the tumour had been excised is shown in
the Table. Five separate experiments
were carried out with rats bearing the
Effect of pre- and postoperative MTP
treatment on local tumour recurrence
MAC. In Exp. 5 (Table), when
tumours were barely palpable, one group
of 9 animals was treated s.c. on the flank
opposite to the tumour-inoculation site on
Days -7 and -3 with 10 jug MTP. The
tumour was excised on Day 0 and the
animals were treated with MTP every 2
days to the end of the experiment. The 2
control groups received only saline pre-
and postoperatively or saline preoper-
atively and MTP postoperatively. The
animals were examined for local tumour
recurrence and for the size of the tumours
E
0
w
N
W- 0
2
0.3
0.03H. EL KAPPANY ET AL.
TABLE.-Effect of MTP on recurrence and size of tumour in animals from which their
tumour had been excised
Ttumour type/host Treatment protocol
Number of animals with tumour/total number
and tumour size (in parentheses cm2 + s.d.)
in (different experiments (given by Arabic
numerals)
Exp.
Day 14-15
Exp.
MAC/Fislier rats 0-900 saline, after surgery
10 tLg MTP, after surgery
10 Hg MTP, before and after
surgery
C12TSV5S/Hamsters 0-9% saline, after suigeryr
AITP, after surgery
MAlTP, before and after surgery
1. 4/4 (6-25 + 0.32) ;*
3. 10/10 (3-42 + 0-54);
5. 9/9 (12-5 +082)
1. 2/4 (1-56 + 0-12);t
3. 7/8 (1-46 + 1-06);
5. 9/9 (6-9 + 0.72)
5. 4/9 (5-8 + 0-51)
Daty 20
1.3/10(1-34+0-57)
2. 2/6 (4 85)t§
1.0/10
2. 1/8 (1-5) §
2. l/9 (1-5) §
2. 4/4 (5-06 +0.07)
4. 5/5(12-25+0-12)
2. 2/4 (3-84 + 0 26)
4.5/5 (6-76+ 0-16)
Day 30-31
1. 4/10 (2-25 + 1-82)
1. 0/10
* In Exps. I and 2, the diameter of the tumour at surgery vas 0 5-1 cm, it was 1-2 cm in Exp. 3 and 2-3
cm in Exp. 4.
t All MTP-treated groups shown a significant reduction in tumotur size (P < 0-01) below that of their
respective saline controls.
t Average of 2 values.
§ In Exp. 2, animals free of recurring tumours were inoculated s.e. withl 106 C12TSV5S cells and the
tumour incidence 15 days later was determined. It was 3/4 in saline, 3/7 in animals receiving post-surgical
MTP, and 2/8 in control animals receiving pre- and post-surgical MTP.
that developed. It was found that tumour
recurrence was 100% in control animals
and in those treated with MTIP post-
operatively. The incidence was reduced to
45%0 in animals receiving MTP pre- and
postoperatively (Table).
Cl2TSV5S.-When the same experiment
(Exp. 2, Table) was carried out with the
Cl2TSV5S tumour in hamsters, 2/6 (33%0)
animals developed local tumour in ham-
sters treated pre- and postoperatively with
saline, whereas 1/8 (12-5%) developed
tumour in the postoperative MTP group
and 1/9 (11%) in animals treated pre- and
postoperatively with MTP. In this experi-
ment, the animals which failed to develop
a tumour in 30 days were challenged s.c.
with 106 Cl2TSV5S cells. It was noted that
within 14 days 3/4 (75%0) animals of the
control group developed tumours at the
inoculation site, whereas 3/7 (43%0) de-
veloped tumour in the postoperative
MTP group and only 2/8 (25%) in those
treated pre- and postoperatively with
MTP.
DISCUSSION
When a new antitumour immuno-
adjuvant becomes available, it has to be
compared with currently used immuno-
therapeutic agents against cancer. The
development of MTP in our laboratory as
a potential antitumour immunoadjuvant
thus made the present study necessary.
In addition, it was felt that ifMTP proved
to be comparable or superior to other
immunoadjuvants, it should be tested in
a simulated human-cancer model in which
immunotherapy is used for the prevention
of tumour recurrence and for slowing the
growth ofthe recurring tumour after cyto-
reductive therapy.
The results from the comparative study,
and in the R3327 animal tumour model,
indicated that MTP was superior to other
adjuvants during the early period (up to
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Day 15), since both the incidence and
growth rate of tumours were significantly
reduced by MTP treatment. By these
criteria, the adjuvants could be graded in
their order of effectiveness as follows:
MTP, levamisole, BCG, pyran copolymer
and C. parvum. After Day 15, the anti-
tumour effect of immunoadjuvants
dropped and tumour growth rate in-
creased. However, even on Day 20, when
most of the immunoadjuvants had lost
their effectiveness (and tumour size was
thesameinuntreatedand treated animals),
MTP-treated animals had an average
tumour size still significantly lower than
that of the controls.
In several previous attempts to obtain
an antitumour effect from MTP given by
intratumoral inoculation in several
tumour-host models carrying poorly
differentiated transplantable tumours, we
had no success. When MTP was compared
with C. parvum and BCG with small (0 3-
0-5cm diameter) and large (1.0-3 0cm
diameter) fast-growing R3327A tumour,
the 3 products all failed to produce either
a regression or a decrease in the growth
rate of this tumour. Intratumoral lev-
amisole was also ineffective with a large
R3327A tumour. On the other hand,
intratumoral treatment of an s.c. well-
differentiated R3327 tumour, - 0-5 cm in
diameter, yielded results which showed
that both MTP and BCG were effective in
reducing the growth rate of the tumour,
though there were no cures. This indicates
that the use of either MTP or BCG intra-
tumoral immunotherapy would be effec-
tive only when the tumour was well differ-
entiated. Indeed, the effectiveness of
intratumoral BCG is mostly observed in
Stage I lung-cancer patients, and is
minimal against advanced lung cancer.
Our observation that MTP was as effective
intratumorally as BCG suggests further
assessment of intratumoral MTP as a
replacement of intratumoral BCG. It is
well known that BCG elicits certain un-
desirable side-effects in cancer patients.
Another comparison of MTP with P
copolymer, BCG and C. parvum was made
when 106 R3327A tumour cells admixed
with optimum doses of immunoadjuvants
in mineral oil were inoculated s.c. into
rats. MTP and C. parvum delayed but did
not prevent tumour takes, whereas BCG
and P copolymer were totally ineffective
(results not described in text). This
observation indicates that the number of
injected R3327A cells (106) was high and
that they multiplied rapidly before the
immunoadjuvants could deliver an effec-
tive modulating signal to the immune
system to destroy their increasing num-
bers. The ability ofMTP to control growth
without preventing tumour take indicates
that this substance does indeed control
tumour proliferative capacity, and its
action is comparable to that of C. parvum
and superior to those of BCG and P
copolymer. The last comparison was of
the role of oral MTP and levamisole in
preventing tumour take and tumour
growth. Both substances were equally
effective in delaying tumour appearance
and reducing tumour growth. The advan-
tage of oral MTP is noteworthy because of
its convenient administration as a substi-
tute for levamisole, which is normally
given orally and has some toxicity. It is
interesting to note that muramyl di-
peptide (MDP), which is a known im-
munoadjuvant in cell walls of bacteria,
also enhances immune reactions when
given to animals by the oral route (Chedid
et al., 1978).
These comparisons indicate that MTP
provides equal or superior antitumour
activity when it is given s.c. to animals,
and is also effective when given by those
routes which are favoured for an immuno-
adjuvant: viz. intralesional BCG and oral
levamisole.
Comparisons between adjuvants other
than MTP have been reported in several
studies. Mathe et al. (1973) compared the
immunoprophylactic effects of BCG,
MER, C. parvum, poly I-poly C and poly
A-poly U administration before tumour
(L 1210 and Lewis lung tumour) inocula-
tion, and observed no significant increases
in survival times. Proctor et al. (1977)710 H. EL KAPPANY ET AL.
found that BCG, levamisole and glucan
administered in 4 dose levels (2, 5, 25 and
250 pg/mouse) i.p. as well as i.d. to 4
limbs were ineffective in delaying s.c. B16
melanoma.
Bruley-Rosset et al. (1978) compared
the immunomodulating effects ofBCG and
levamisole, and found that in young mice
a single BCG injection activated cell-
mediated and humoral immunities, as well
as inducing suppressor cells, whereas
levamisole had no effect. In aged mice,
BCG inhibited humoral response and
generated suppressor cells, whereas lev-
amisole restored humoralimmune response
and failed to induce suppressor cells. This
finding could explain the superiority of
levamisole over BCG in our experiments.
The effectiveness of MTP immuno-
therapy in cancer treatment was appreci-
ated when it was administered after
removal of tumour and the recurrence
and growth rates of the tumour were
measured. The tumours used were MAC
and C12TSV5S, one of which recurs locally
in all animals after surgery, whereas the
other one, which is more immunogenic,
recurs locally in 40-50% ofthe animals.
In the first series of two experiments in
Fisher rats bearing MAC tumour, MTP
treatment after tumour excision prevented
regrow thin 50% of the animals.
The tumours in this case were excised at
an early stage of development (<1 cm
diameter). Large tumours upon excision
either left behind more tumour cells or the
animals were more immunosuppressed, so
that MTP could not prevent tumour re-
growth. However, with both small and
large tumours, the growth rate of residual
tumour cells was inhibited by MTP, as
evidenced by smaller tumours than in
excised controls.
In Exp. 3 (Table), in which the time
course of tumour recurrence was deter-
mined, the effect of MTP was quite
evident as a slow onset of tumour appear-
ance, small tumour and prolonged sur-
vival (not shown). However, since all the
animals finally died of cancer, it was
indicated that MTP-potentiated host de-
fences were finite, and could be over-
powered by the growing tumour.
When the same experiments were re-
peated with a slightly more immunogenic
Cl2TSV5S tumour, the results were more
encouraging. MTP-mediated host defences
were notovercomebyresidual tumour, and
in only one experiment was there tumour
recurrence. This promising observation
could have been aidedbytheslowergrowth
of this tumour and/or the insufficient
number of cells left behind after surgery,
since 40% of the excised controls also
formed no local tumours.
We were also able to show that, in the
case of Cl2TSV5S tumour, challenge of 106
tumour cells in animals with no apparent
recurrent tumours (untreated or MTP-
treated), tumours grew at the challenge
site in 75% of the animals excised oftheir
tumours, whereas the tumour takes were
lower (25-43%) in post- or pre- and post-
operatively MTP-treated animals.
Our observation that pre- and post-
operative MTP appeared to be superior
to postoperative MTP alone can only be
commented upon briefly. Such observa-
tions require extensive confirmatory
studies, with many animals in this and
other tumour systems, to generalize from
ourobservations, since the differences have
poor significance. Such studies would be
important, insofar as they could suggest
the timings of immunotherapeutic man-
oeuvres, for tumour-bearers who are to
undergo tumour surgery.
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